Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of the Liver Italian Program (CLIP) score. The 56 patients in the TACE group received a total of 123 treatment courses. The median follow-up period was 16 months (range, 1-67 mo) in the TACE group and 5 months (range, 1-77 mo) in the supportive care group. Survival rates at 12, 24, and 30 months in patients receiving TACE were 74.3%, 52.1%, and 38.8% respectively, with a median survival time of 25 month whereas in supportive care patients the rates we 39.4%, 25.4%, and 19%, respectively, with a median survival time of 7 months (P =.0004). At univariate analysis, TACE, tumor type, presence of ascites, alpha-fetoprotein serum level, CLIP score, and Okuda stage were associated significantly with survival. Only TACE and CLIP score proved to be independent predictors of survival at multivariate analysis. Conclusions: TACE is an effective therapeutic option for cirrhotic patients with unresectable HCC and a CLIP score of 3 or less

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study / Biselli, Maurizio; Andreone, Pietro; Gramenzi, Annagiulia; Trevisani, Franco; Cursaro, C.; Rossi, Cristina; Ricca Rossellini, S.; Cammà, C.; Lorenzini, S.; Stefanini, G. F.; Gasbarrini, G.; Bernardi, Mauro. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - 3:9(2005), pp. 918-925. [10.1016/S1542-3565(05)00425-8]

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study

ANDREONE, PIETRO;BERNARDI, MAURO
2005

Abstract

Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of the Liver Italian Program (CLIP) score. The 56 patients in the TACE group received a total of 123 treatment courses. The median follow-up period was 16 months (range, 1-67 mo) in the TACE group and 5 months (range, 1-77 mo) in the supportive care group. Survival rates at 12, 24, and 30 months in patients receiving TACE were 74.3%, 52.1%, and 38.8% respectively, with a median survival time of 25 month whereas in supportive care patients the rates we 39.4%, 25.4%, and 19%, respectively, with a median survival time of 7 months (P =.0004). At univariate analysis, TACE, tumor type, presence of ascites, alpha-fetoprotein serum level, CLIP score, and Okuda stage were associated significantly with survival. Only TACE and CLIP score proved to be independent predictors of survival at multivariate analysis. Conclusions: TACE is an effective therapeutic option for cirrhotic patients with unresectable HCC and a CLIP score of 3 or less
2005
3
9
918
925
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study / Biselli, Maurizio; Andreone, Pietro; Gramenzi, Annagiulia; Trevisani, Franco; Cursaro, C.; Rossi, Cristina; Ricca Rossellini, S.; Cammà, C.; Lorenzini, S.; Stefanini, G. F.; Gasbarrini, G.; Bernardi, Mauro. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - 3:9(2005), pp. 918-925. [10.1016/S1542-3565(05)00425-8]
Biselli, Maurizio; Andreone, Pietro; Gramenzi, Annagiulia; Trevisani, Franco; Cursaro, C.; Rossi, Cristina; Ricca Rossellini, S.; Cammà, C.; Lorenzini, S.; Stefanini, G. F.; Gasbarrini, G.; Bernardi, Mauro
File in questo prodotto:
File Dimensione Formato  
CEAT.pdf

Accesso riservato

Dimensione 1.99 MB
Formato Adobe PDF
1.99 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237301
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 23
social impact